Scholars@Duke
Rani Bansal

Rani Bansal

Assistant Professor of Medicine
Medicine, Medical Oncology
Box 3381, Seeley Mudd Building, Durham, NC 27710

Scholarly Works - Conferences

Overall survival by genomic profile in HER2-positive (HER2+) metastatic breast cancer (mBC): A large US clinico-genomic database study.

Conference Journal of Clinical Oncology · June 1, 2026 1045Background: Over the past few years, the landscape of treatment for HER2+ breast ... Full text Cite

Abstract P1-02-04: Impact of abemaciclib dose escalation on compliance and safety in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer

Conference Clinical Cancer Research · June 13, 2025 AbstractBackground: Abemaciclib, a cyclin dependent kinase 4/6 inhibitor (CDK4/6i), is approved for the treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) ... Full text Cite

Abstract P5-08-15: Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2) negative metastatic breast cancer

Conference Clinical Cancer Research · June 13, 2025 AbstractBackground: Antibody drug conjugates (ADCs) are composed of a monoclonal antibody with a cytotoxic payload designed to deliver targeted therapy with minimal damage to non-cancerous cells.1 Recent tri ... Full text Cite

Abstract PO4-24-08: Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy

Conference Cancer Research · May 2, 2024 AbstractIntroduction:Phyllodes tumors (PT) are rare fibroepithelial tumors of the breast, comprising ~1% of all breast cancers, a subset of which have considerable malignant ... Full text Cite

Abstract PO3-19-04: The CROWN STUDY: A multicenter prospective cohort study of cardiovascular outcomes in premenopausal women with hormone receptor positive breast cancer treated with ovarian suppression and an aromatase inhibitor

Conference Cancer Research · May 2, 2024 AbstractBackground: Treatment for premenopausal women with high or intermediate risk hormone receptor (HR)+ breast cancer (BC) includes the concurrent use of ovarian function suppression (OFS) and an aromata ... Full text Cite

Abstract 6472: Response to PARP inhibitors in patients with breast cancer metastatic to the central nervous system

Conference Cancer Research · March 22, 2024 AbstractBackground: Central nervous system (CNS) metastasis from breast cancer can be challenging to treat due to the limited blood brain barrier penetration of many systemic therapies. PARP inhibitors (PARP ... Full text Cite

Abstract HER2-12: HER2-12 Genomic and Transcriptomic Landscape of HER2-Low Breast Cancer

Conference Cancer Research · March 1, 2023 AbstractIntroduction: Breast cancer has pioneered precision medicine with prognostic and predictive subtypes, defined by immunohistochemistry (IHC). Novel therapeutic strategies have led to the emergence of ... Full text Cite